Drug intelligence / Profile preview

MenABCWY+¼OMV

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MenABCWY+¼OMV is an investigational multivalent meningococcal vaccine designed to provide protection against *Neisseria meningitidis* serogroups A, B, C, W, and Y. This specific formulation contains recombinant Meningococcal B (rMenB) antigens (50 µg per antigen), a quarter dose (6.25 µg) of Outer Membrane Vesicles (OMV), and a fully lyophilized MenACWY vaccine component. It aims to induce an immune response to prevent meningococcal disease.

Targets

Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)

Beyond the preview

Go deeper on MenABCWY+¼OMV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MenABCWY+¼OMV.

Explore the full profile